SPRB Spruce Biosciences Inc

Citizens reiterated $SPRB Market Outperform-$144 and said -- The virtual Advance Sanfilippo Community Conference that wrapped yesterday (9/23) highlighted TA-ERT as the leading emerging therapy for MPS IIIB, with FDA commentary reinforcing the need for regulatory flexibility ahead of SPRB's expected 4Q26 BLA submission.

$SPRB this is obivously a tiny market overall, but I think its made even smaller by the way TA-ERT is administered (directly into the brain weekly) and the side effects. I'm guessing this is just a tiny little ultra rare market and these price targets in the 100+ range are likely to be a big bust

$SPRB or maybe you should learn to actually do research on the topic before you start arguing about topics you’re completely clueless about ? I’m sure you heard this before , but your name fits

$SPRB are the currently approved in globally? The current scope and valuation is based on what the current expectations are and those potential revenues. You want to start adding stuff and act like you’re the only one that had this information like the presentation hasn’t been circled for years .

$SPRB we can all make up numbers but drugs of this kind (I know this is somewhat novel) are usually around $350K.

$SPRB Just gotta be patient here. The PRV alone is worth roughly 1.5 times the current market cap.

$SPRB SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenuated Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 55th Child Neurology Society (CNS) Annual Meeting, taking place October 14–17, 2026, in Montréal, Québec, Canada. The poster will be available on the Spruce Biosciences website following the presentation.

$SPRB Presentation Date & Time: October 15, 2026, 12:30 p.m. – 1:45 p.m. EDT and 5:30 p.m. – 7:30 p.m. EDT Presenter: Ilyas Okur, M.D., Professor of Pediatrics and Pediatric Metabolism Specialist

$SPRB Any catalyst in the remaining 2026? I am thinking about tax loss selling here. Average is $59 but running out of patience. JMO